Tag Archives: Health Canada

Takeaways from the Post-Approval Summit

Dr. Richard Gliklich, president of Quintiles Outcome and a professor at Harvard Medical School, highlights the most prominent post-approval issues and risks coming out of this year’s Post-Approval Summit, held on May 7th-8th. Brand managers prodding products across the regulatory finish line to commercialization are finding themselves in yet another race, instead of in the […]
Posted in Technology | Also tagged , , , , , , , , , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada‚Äôs National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Posted in Global, healthcare, IP, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta